MedTrace Logo

Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea

NCT01150942 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2014-01-30

No results posted yet for this study

Summary

To assess the immunogenicity and safety of the vero cell-derived inactivated JE vaccine in Korean healthy children aged 12\~23 months

Conditions

  • Japanese Encephalitis

Interventions

BIOLOGICAL

JE vaccine

3 times, IM

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Gachon University Gil Medical Center

    collaborator OTHER

  • Inha University Hospital

    collaborator OTHER

  • Inje University

    collaborator OTHER

  • Korea Cancer Center Hospital

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • The Catholic University of Korea

    collaborator OTHER

  • Ewha Womans University

    collaborator OTHER

  • Wonju Severance Christian Hospital

    collaborator OTHER

  • Kyunghee University Medical Center

    collaborator OTHER

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Hoan Jong Lee, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
23 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2012-09-30
Completion
2013-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01150942 on ClinicalTrials.gov